Journal
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Volume 18, Issue 4, Pages 1171-1173Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/jcrt.JCRT_802_19
Keywords
68Ga-DOTATOC positron-emission tomography; computed tomography; desmoid tumor; mesenteric fibromatosis; neuroendocrine tumor; somatostatin receptor
Categories
Ask authors/readers for more resources
Mesenteric fibromatosis is a locally aggressive fibroblastic lesion with a high recurrence rate. This study found that the tumor cells express somatostatin receptors and suggested that it could be one of the potential causes of false-positive results in 68Ga PET/CT.
Mesenteric fibromatosis (desmoid tumor) is a locally aggressive fibroblastic lesion, characterized by a high recurrence rate that makes treatment challenging. Currently, there is no evidence-based treatment approach. We report the case of a female patient with a history of neuroendocrine tumor, who underwent( 68)Ga-DOTATOC positron-emission tomography/computed tomography (PET/CT), showing increased focal abdominal uptake suggestive of disease relapse. Histological examination revealed typical findings of fibromatosis. These findings indicate the expression of staining for somatostatin receptors (SSTRs) on fibromatosis cell surface and suggest to include fibromatosis among the potential causes of false-positive results at 68Ga PET/CT. Moreover, SSTRs expressed in desmoid tumors could be further investigated as a therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available